Partnership to target solid oral dosage form product segment
Avantor Performance Materials has signed an agreement with Rubicon Research of Mumbai, India to develop and market a novel gastro-retentive excipient that enables the delivery of molecules with a window of absorption.
The US firm says this excipient will enable the industry to develop more options in a niche segment where the benefit of targeted delivery will result in significant therapeutic advantage.
Under the terms of the pact, Rubicon’s proprietary technology will be combined with Avantor’s expertise in manufacturing and marketing to develop these next-generation products.
‘We are delighted to be working with an exceptional partner like Rubicon in this development effort,’ said Paul Smaltz, executive VP of pharmaceuticals and the Americas for Avantor.
‘The combination of Rubicon’s groundbreaking technology and our strong position in the global marketplace for functional excipients will result in outstanding products to help our pharmaceutical customers in their pursuit of patient dosage compliance, and safety.’
The partners will collaborate on key elements of the process of bringing new excipients to the pharmaceutical market, including optimised commercial manufacturing and production, full regulatory registrations and approvals from the US FDA to move toward full commercialisation and potential licensing of the excipient materials.
The two companies aim to launch initial products next year.
‘The Rubicon team is excited to work with Avantor in introducing this novel polymeric material as a functional excipient,’ said Rubicon Research’s CEO Pratibha Pilgaonkar.
‘This material will provide solutions to the global pharmaceutical industry for molecules with challenging therapeutic requirements, either from the pipelines of innovator companies or for life cycle management opportunities for already marketed products.’